These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 32353743)

  • 1. Purposing Saikosaponins for the treatment of COVID-19.
    Bahbah EI; Negida A; Nabet MS
    Med Hypotheses; 2020 Jul; 140():109782. PubMed ID: 32353743
    [No Abstract]   [Full Text] [Related]  

  • 2. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools.
    Kong Q; Wu Y; Gu Y; Lv Q; Qi F; Gong S; Chen X
    Biomed Pharmacother; 2020 Aug; 128():110316. PubMed ID: 32505821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs and the renin-angiotensin system in covid-19.
    Aronson JK; Ferner RE
    BMJ; 2020 Apr; 369():m1313. PubMed ID: 32241880
    [No Abstract]   [Full Text] [Related]  

  • 4. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
    Almerie MQ; Kerrigan DD
    Med Hypotheses; 2020 Oct; 143():109883. PubMed ID: 32492562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dapsone and doxycycline could be potential treatment modalities for COVID-19.
    Farouk A; Salman S
    Med Hypotheses; 2020 Jul; 140():109768. PubMed ID: 32339778
    [No Abstract]   [Full Text] [Related]  

  • 6. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
    Choudhary S; Silakari O
    Virus Res; 2020 Nov; 289():198146. PubMed ID: 32866534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?
    Oscanoa TJ; Romero-Ortuno R; Carvajal A; Savarino A
    Int J Antimicrob Agents; 2020 Sep; 56(3):106078. PubMed ID: 32629115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sitagliptin Repositioning in SARS-CoV-2: Effects on ACE-2, CD-26, and Inflammatory Cytokine Storms in the Lung.
    Dastan F; Abedini A; Shahabi S; Kiani A; Saffaei A; Zare A
    Iran J Allergy Asthma Immunol; 2020 May; 19(S1):10-12. PubMed ID: 32534505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proposed use of thalidomide for the cytokine storm of COVID-19.
    Goihman-Yahr M
    Clin Dermatol; 2020; 38(4):508. PubMed ID: 32972614
    [No Abstract]   [Full Text] [Related]  

  • 10. Déjà vu: Stimulating open drug discovery for SARS-CoV-2.
    Ekins S; Mottin M; Ramos PRPS; Sousa BKP; Neves BJ; Foil DH; Zorn KM; Braga RC; Coffee M; Southan C; Puhl AC; Andrade CH
    Drug Discov Today; 2020 May; 25(5):928-941. PubMed ID: 32320852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?
    Severa M; Farina C; Salvetti M; Coccia EM
    Front Immunol; 2020; 11():1459. PubMed ID: 32655578
    [No Abstract]   [Full Text] [Related]  

  • 12. Is SARS-CoV-2 associated with liver dysfunction in COVID-19 patients?
    Ali N
    Clin Res Hepatol Gastroenterol; 2020 Sep; 44(4):e84-e86. PubMed ID: 32471656
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug targets for COVID-19 therapeutics: Ongoing global efforts.
    Saxena A
    J Biosci; 2020; 45(1):. PubMed ID: 32661214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
    Huang Y; Xie C; Chen X; Hong Q; Huang H
    Pharmacol Res; 2020 Sep; 159():104959. PubMed ID: 32505834
    [No Abstract]   [Full Text] [Related]  

  • 15. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology.
    Dal Moro F; Livi U
    Clin Immunol; 2020 May; 214():108414. PubMed ID: 32272196
    [No Abstract]   [Full Text] [Related]  

  • 16. Potential therapeutic targets and promising drugs for combating SARS-CoV-2.
    Zhou H; Fang Y; Xu T; Ni WJ; Shen AZ; Meng XM
    Br J Pharmacol; 2020 Jul; 177(14):3147-3161. PubMed ID: 32368792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A protein interaction map identifies existing drugs targeting SARS-CoV-2.
    Cava C; Bertoli G; Castiglioni I
    BMC Pharmacol Toxicol; 2020 Sep; 21(1):65. PubMed ID: 32883368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging pharmacotherapies for COVID-19.
    Salvi R; Patankar P
    Biomed Pharmacother; 2020 Aug; 128():110267. PubMed ID: 32410772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioactive compounds with possible inhibitory activity of Angiotensin-Converting Enzyme-II; a gate to manage and prevent COVID-19.
    Dabaghian F; Khanavi M; Zarshenas MM
    Med Hypotheses; 2020 Oct; 143():109841. PubMed ID: 32425303
    [No Abstract]   [Full Text] [Related]  

  • 20. Is Coronavirus Disease 2019 (COVID-19) seen less in countries more exposed to Malaria?
    Sargin G; Yavaşoğlu Sİ; Yavasoglu I
    Med Hypotheses; 2020 Jul; 140():109756. PubMed ID: 32344306
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.